Premarket Decliner
PALI Palisade Bio7.08+1.05+17.4%
Premarket:6.61-0.47 (-6.6%)
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Globe NewswireThu, 2-May 8:30 AM
PALI Palisade Bio3.52+0.87+32.8%
Premarket:2.34-1.18 (-33.5%)
Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Globe NewswireMon, 3-Apr 8:30 AM
Premarket Gainer
PALI Palisade Bio0.81-0.07-8.5%
Premarket:1.40+0.59 (+73.9%)
Palisade Bio (Nasdaq: PALI) Receives FDA "Study May Proceed" Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery
Globe NewswireTue, 22-Mar 8:30 AM
PALI Palisade Bio3.48+0.21+6.4%
Premarket:4.06+0.58 (+16.7%)
Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery
Globe NewswireThu, 29-Jul 8:15 AM
PALI Palisade Bio5.25-0.08-1.5%
Premarket:6.59+1.34 (+25.5%)
Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery
Globe NewswireThu, 13-May 7:00 AM
